Discover
All In Investing
All In Investing
Author: Adam Olivetti
Subscribed: 6Played: 14Subscribe
Share
© Adam Olivetti
Description
Are you working for money? Or does your money work for you? This podcast is going to teach you strategies we used to get out of debt and start making real money to change your future. Oh and we want to help out animal shelters because who doesn’t like saving animals.
33 Episodes
Reverse
Like and share on IG @allininvestingpodcast to your IG story!!! Vettz and Papi dive back in to let you know about levered ETFs specifically the TQQQ which can be 2x or 3x multiple of the general market performance in the short term. They also get some non fungible token talk and crypto chat in, even mention more emotional management during volatile times.
Did you like and share to story our post @allininvestingpodcast on IG? If not you are banned from listening until doing so. Vettz and G-Money dive back in after a bit of a break from things to recharge and reload. Here G$ will mention how he is going to manage a position on Helix (ticker HLX) an oil company he has made great gains with, more importantly we discuss the tax advantages to long term holding.
Vettz and G-Money pop back in after some time off to reset and refuel. Market has been getting bloody but there is hope on the horizon as Hexo Corporation has acquired a strategic partner, Vettz will talk some Penny Stonks, and the lads finish up with a base level conversation around the cryptocurrency Ethereum. Stonks only go up? We hope!
Vettz and Papi jump back in for a general overview on an up and coming pharma stock that has the potential to revolutionize chemotherapy. Nucana develops protective moieties called phosphoramidate components for chemotherapy drugs. These moieties change the chemical property of traditional chemotherapy drugs allowing the chemo drugs to enter cancer cells independently of nucleoside transporters (easier entry) and protects them from cancer cells’ defenses called deaminase enzymes, which break down chemotherapy molecules. This allows delivery of active drug faster and more protected for a better response to therapy. Vettz also touches on the current dilemma of Cathie Wood at ARK invest. Currently ARK’s popularity is becoming a bit of a problem as their own size is becoming their worst enemy. You’ll have to listen to find out!
Vettz drops back in to hide a full analysis of the future prospect of Baozun (NYSE:BZUN). Baozun is a full end to end suite of services for e-commerce for major Western brands (Nike, Microsoft, Gucci, Canada Goose) to set up their stores online in China. As the Chinese environment and consumer has much different taste and responds differently than the western consumer. Baozun helps companies place their product in the right place at the right time online to boost sales. With infrastructure, fulfillment, and large staff worries, is Baozun still set to go to the moon? Listen in!




